Anticholinergics in the treatment of chronic obstructive pulmonary disease

Respiration

Volumn 69, Issue 4, 2002, Pages 372-379

  Beeh, Kai Michael ^a   Welte, Tobias ^b   Buhl, Roland ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

Author keywords

Agonists; Anticholinergics; Chronic obstructive pulmonary disease

Indexed keywords

BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; LONG ACTING DRUG;

BRONCHUS MUCUS; BRONCHUS MUSCLE; CHOLINERGIC SYSTEM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; DISEASE EXACERBATION; DRUG POTENCY; DYSPNEA; EXERCISE TOLERANCE; HEALTH CARE COST; HUMAN; LUNG FUNCTION; MORBIDITY; MORTALITY; MUSCLE TONE; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; VAGUS NERVE STIMULATION;

ADRENERGIC BETA-AGONISTS; CHOLINERGIC ANTAGONISTS; HUMANS; IPRATROPIUM; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SCOPOLAMINE DERIVATIVES;

EID: 0036058359     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000063278     Document Type: Review

References (86)

1. Ipratropium bromide
2. Oxitropium bromide
3. Current estimates from the National Health Interview Survey, 1994
4. Global Initiative for chronic obstructive lung disease (GOLD)
5. Nonbronchodilator effects of pirbueterol and ipratropium in chronic obstructive pulmonary disease
6. Neural control of human airways in health and disease
7. Rationale for the use of antimuscarinics in obstructive airway disease
8. Muscarinic receptor subtypes in airways
9. The pharmacological properties of tiotropium
10. Tiotropium bromide (Ba 679 BR), a novel long-acting muscarinic antagonist for the treatment of obstructive airways disease
11. The pharmacology of oxitropium bromide
12. Acute bronchodilating effects of ipratropium bromide and theophylline in chronic obstructive pulmonary disease
13. Is an anticholinergic agent superior to a beta-agonist in improving dyspnea and exercise limitation in COPD?
14. Comparison of ipratropium bromide and albuterol in chronic obstructive pulmonary disease: A three-center study
15. The future for tiotropium
16. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD
17. Acute effect of pretreatment with single conventional dose of salmeterol on dose-response curve to oxitropium bromide in chronic obstructive pulmonary disease
18. A comparison of bronchodilating effects of salmeterol and oxitropium bromide in stable chronic obstructive pulmonary disease
19. Nebulized bronchodilators for out-patient management of stable chronic obstructive pulmonary disease
20. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone
21. Tiotropium (TIO) reduces the incidence of COPD exacerbations compared to ipratropium (IB)
22. Tiotropium (Spiriva): Mechanistical considerations and clinical profile in obstructive lung disease
23. Comparison of the bronchodilator effect of aminophylline and ipratropium bromide in COPD
24. 1
25. The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD
26. A comparison of the bronchodilating effects of a beta-2 adrenergic agent (albuterol) and an anticholinergic agent (ipratropium bromide), given by aerosol or in sequence
27. Management of chronic obstructive pulmonary disease
28. A multicenter study of nebulized bronchodilator solutions in chronic obstructive pulmonary disease
29. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD
30. Historical view of the use of parasympatholytic agents in the treatment of respiratory disorders
31. Improvement in perceived dyspnea in patients receiving tiotropium vs ipratropium bromide (Atrovent®)
32. Ipratropium bromide
33. Safety and side-effects of anticholinergic bronchodilators
34. Anticholinergic, antimuscarinic bronchodilators
35. 3H] Ba 679 BR, a slowly dissociating muscarinic antagonist, in human lung: Radioligand binding and autoradiographic mapping
36. Bronchodilator reversibility, exercise performance and breathlessness in stable chronic obstructive pulmonary disease
37. 2-adrenergic agonist and an anticholinergic agent given by sequential inhalation in patients with severe chronic obstructive pulmonary disease
38. Bronchodilating effects of combined therapy with clinical dosages of ipratropium bromide and salbutamol for stable COPD
39. Comparative dose-response study of three anti-cholinergic agents and fenoterol using a metered dose inhaler in patients with chronic obstructive pulmonary disease
40. Comparison of bronchodilator effects of fenoterol/ipratropium bromide and salbutamol in patients with chronic obstructive lung disease
41. Human airway smooth muscle cells express and release RANTES in response to T helper 1 cytokines: Regulation by T helper 2 cytokines and corticosteroids
42. Bronchodilator responses to anti-cholinergic and beta-adrenergic agents in acute and stable COPD
43. A comparison of inhaled ipratropium, oral theophylline plus inhaled β-agonist, and the combination of all three in patients with COPD
44. A comparison of the effects of ipratropium bromide and metaproterenol sulfate in acute exacerbations of COPD
45. Abnormalities of pulmonary function in patients with congestive heart failure, and reversal with ipratropium bromide
46. A comparison of the bronchodilating effects of oxitropium bromide and fenoterol in patients with chronic obstructive pulmonary disease
47. Ba 679 BR, a new long-acting antimuscarinic bronchodilator: A pilot dose-escalation study in COPD
48. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: A pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD)
49. Efficacy of salmeterol xinafoate in the treatment of COPD
50. Localization of muscarinic receptor subtype mRNAs in human lung
51. Visualization of muscarinic M4 mRNA and M4 receptor subtypes in rabbit lung
52. Effect of ipratropium bromide treatment on oxygen saturation and sleep quality in COPD
53. Underdiagnosis and geographic differences in COPD prevalence in Spain
54. Bronchodilator reversibility to low and high doses of terbutaline and ipratropium in COPD
55. Bronchodilator reversibility to low and high doses of terbutaline and ipratropium bromide in patients with chronic obstructive pulmonary disease
56. Acute bronchodilator trials in chronic obstructive pulmonary disease
57. Is oral theophylline effective in combination with both inhaled anticholinergic and inhaled β-agonist in the treatment of stable COPD?
58. The many faces of airway inflammation. Asthma and chronic obstructive pulmonary disease
59. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease
60. Comparison of the effects of salmeterol and ipratropium bromide on exercise performance and breathlessness in patients with stable chronic obstructive pulmonary disease
61. Pulmo cardialis: Effekt inhalativer bronchodilatatoren auf den atemwegswiderstand bei akuter linksventrikulärer funktionsstörung
62. Extended therapy with ipratropium is associated with improved lung function in patients with COPD
63. Definitions in respiratory disease: The 'not simply asthmatic' patient
64. The bronchospasmolytic test with anticholinergic drugs and sympathomimetics: Differences between body plethysmography and spirometry measuring procedures
65. Cardiac arrhythmias after inhaled bronchodilators in patients with COPD and ischemic heart disease
66. Epidemiology of chronic obstructive pulmonary disease
67. Decreased duration of emergency department treatment of chronic obstructive pulmonary disease exacerbations with the addition of ipratropium bromide to β-agonist therapy
68. ERS Consensus Statement: Optimal assessment and management of COPD
69. Bronchodilatory responses to formoterol, ipratropium, and their combination in patients with stable COPD
70. Effect of Ba 679 BR, a novel long-acting anticholinergic agent, on cholinergic neurotransmission in guinea pig and human airways
71. Comparison of the anticholinergic bronchodilator ipratropium bromide with metaproterenol in chronic obstructive pulmonary disease
72. Influence of 1-year treatment period on responses to anticholinergic inhalation in patients with chronic obstructive pulmonary disease
73. Long-term effects of inhaled anticholinergic drug on lung function, dyspnea, and exercise capacity in patients with chronic obstructive pulmonary disease
74. Routine nebulized ipratropium and albuterol together are better than either alone in COPD
75. Pathology of chronic obstructive pulmonary disease
76. Effects of theophylline and ipratropium bromide on exercise performance in patients with stable chronic obstructive pulmonary disease
77. Pathogenese, diagnostik und therapie der COPD
78. Anticholinergics as bronchodilators. An action profile
79. A randomized controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease
80. Pharmacokinetics of oxitropium bromide
81. Atropine, scopolamine and related antimuscarinic drugs
82. A comparison of the effects of anticholinergic and β-agonist and combination therapy on respiratory impedance in COPD
83. Tiotropium (Ba 679): Pharmacology and early clinical observations
84. Tiotroium (Spiriva®) improves health status in patients with COPD
85. Superior bronchodilation of once daily tiotropium compared to twice daily salmeterol in patients with COPD